CRF (HUMAN, RAT) | CAS:86784-80-7

We serve CRF (HUMAN, RAT) CAS:86784-80-7 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
CRF (HUMAN, RAT)

Chemical Name:CRF (HUMAN, RAT)
CAS.NO:86784-80-7
Synonyms:CRF (HUMAN, RAT)
Corticotropin-releasing factor (human and rat)
Human corticotropin-releasing hormone-41
Rat/human corticotropin-releasing factor
Human CRF(1-41)
 
Physical and Chemical Properties:
Molecular Formula C208H344N60O63S2
Molecular Weight 4757.45
 
Specification:
Appearance:White to off-white powder
Assay:≥98.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:For use/treatment in brain cancer and neurologic disorders.



Contact us for information like CRF (HUMAN, RAT) chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Human CRF(1-41) physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Corticotropin-releasing factor (human and rat) Use and application,Human corticotropin-releasing hormone-41 technical grade,usp/ep/jp grade.


Related News: Three more patients have been confirmed infected with coronavirus in South Korea, bringing the country’s total to 15, the South Korean Centers for Disease Control and Prevention (KCDC) announced in a press release.(3R)-1-azabicyclo[2.2.2]octan-3-ol manufacturer The active ingredient (AI) is the substance or substances that are biologically active within the drug and is the specific component responsible for the desired effect it has on the individual taking it.(S)-2-Benzothiazolyl (Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-methoxyiminothioacetate supplier It does not require a production license for the drug substance, and can be produced in an ordinary chemical plant. As long as it reaches a certain level, it can be used for the synthesis of the drug substance.2-Fluoro-4-methoxybenzonitrile vendor As a result, the Company’s platform is uniquely capable of overcoming numerous limitations associated with the production of cell therapies using patient- or donor-sourced cells, which is logistically complex and expensive and is subject to batch-to-batch and cell-to-cell variability that can affect clinical safety and efficacy.As a result, the Company’s platform is uniquely capable of overcoming numerous limitations associated with the production of cell therapies using patient- or donor-sourced cells, which is logistically complex and expensive and is subject to batch-to-batch and cell-to-cell variability that can affect clinical safety and efficacy.